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Abstract
The Na/glucose cotransporter gene SGLT1 was analyzed in a Japanese patient with congenital glucose-galactose
malabsorption. Genomic DNA was used as a template for amplification by the polymerase chain reaction of each of the 15
exons of SGLT1. The amplification products were cloned and sequenced. About half of the exon 5 clones of the patient
contained a CCT transition, resulting in an Arg135CTrp mutation, whereas the remaining clones contained the normal
exon 5 sequence. In addition, whereas some exon 12 clones exhibited the normal sequence, others showed a
CAgtaggtatcatcCCAgacc mutation at the splice donor site of intron 12 that may result either in the skipping of exon 12
or in read-through of intron 12. Neither the Arg135CTrp mutant nor either of the possible intron 12 mutant proteins
exhibited Na-dependent glucose transport activity when expressed in Xenopus oocytes. Immunocytochemical analysis
indicated, however, that the Arg135CTrp mutant was localized to the oocyte plasma membrane. DNA sequence analysis
revealed that the missense mutation in exon 5 and the splice site mutation in intron 12 were inherited from the proband’s
father and mother, respectively. These results indicate that the patient is a compound heterozygote for this disease, and that
the Arg135CTrp mutant of SGLT1 undergoes normal trafficking to the plasma membrane but is non-functional. ß 2001
Elsevier Science B.V. All rights reserved.
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1. Introduction
Absorption of monosaccharides in the small intes-
tine of mammals is mediated by speci¢c transporters
in the apical membrane of epithelial cells. Glucose
and galactose are actively transported into these cells
by the Na-dependent glucose transporter SGLT1
[1], whereas fructose is transported by Glut5 [2] or
Glut2 [3]. The human SGLT1 gene is located at chro-
mosome 22q13.1, comprises 15 exons, and encodes a
73-kDa hydrophobic protein predicted to contain 14
transmembrane segments [1].
Congenital glucose-galactose malabsorption
(GGM), which was ¢rst described in 1962 [4,5], is
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an autosomal recessive disease characterized by the
selective malabsorption of glucose and galactose,
with the absorption of fructose being unimpaired
[6,7]. OnlyV200 individuals worldwide are currently
known to be a¡ected by GGM [7], ¢ve of whom
reside in Japan [8,9]. We have now studied one of
these Japanese patients and shown that she is a com-
pound heterozygote for defects in SGLT1, exhibiting
a missense mutation in exon 5 and a splice site mu-
tation in intron 12. The protein a¡ected by the mis-
sense mutation in exon 5 exhibited normal tra⁄cking
to the plasma membrane but showed little transport
activity, possibly because of a change in its confor-
mation in the membrane.
2. Materials and methods
2.1. Patient background
The clinical course of the patient will be described
in detail elsewhere. In brief, the proband was the
3234-g product of a normal full-term pregnancy
born to Japanese parents in 1994. Breast feeding be-
gan on the day following birth and frequent watery
diarrhea became noticeable on day 3. On day 7, she
was admitted to the neonatal intensive care unit of
Fukui Red Cross Hospital with symptoms of emaci-
ation, apathy, and severe dehydration and a body
weight of 2674 g. The concentrations of analytes in
serum on admission were as follows: Na, 174 mEq/
l ; K, 4.9 mEq/l; Cl3, 145 mEq/l; urea nitrogen,
39.7 mg/dl; creatine, 0.8 mg/l. Reducing sugars
were found in acidic feces (pH 5.5). The hypertonic
dehydration was treated with parenteral £uid ther-
apy. The diarrhea stopped with the cessation of
breast feeding and started again when breast feeding
was resumed. The patient’s condition did not change
on a lactose-free formula in which lactose was re-
placed with glucose and polysaccharides, nor on
5% glucose solution. The introduction of fructose-
supplemented, carbohydrate-free formula resulted in
a marked improvement in her diarrhea. She grew and
developed normally while continuing with the fruc-
tose-supplemented formula, and was discharged from
the hospital in a healthy state at age 49 days. On the
basis of her clinical course, she was diagnosed with
GGM.
2.2. Molecular biology
Genomic DNA was extracted from whole blood
with the use of an extraction kit (Takara) and used
as the template for ampli¢cation of all 15 exons of
SGLT1 by the polymerase chain reaction (PCR). The
primers (forward and reverse, respectively) were
as follows: 5P-CATTCGCAGGACAGCTCTTA and
5P-TAAAGTGCTTCCAAGTCATT (exon 1); 5P-
TGGCTGGCAAGGCCACTCTT and 5P-GGAT-
CCTTGAATCCTAGAAT (exon 2); 5P-GACATG-
TCTCCTCTCTCTTT and 5P-TTGAACTGGTTG-
ACTGCTAA (exon 3); 5P-CAGGTGGCAGGGA-
TGGGCTA and 5P-ACCTGGGAGTGAAAGCC-
AAT (exon 4); 5P-CACACTTCTGTGGCTCTGAT
and 5P-CGCCTCTTGGTGGGCAGCAT (exon 5);
5P-AATCAGGAGTAGAGAGACTA and 5P-GGG-
TTTGAGGTGCTGGTTTA (exon 6); 5P-CAGA-
AGGCCAGCAGGAAGTA and 5P-CCTCTTCCT-
GAGGCCCTCTA (exon 7); 5P-CCTCTCAGTTT-
CTCAGGCAT and 5P-GACAGACAGGAGTTC-
CTGTA (exon 8); 5P-GACCCAAGATGGCGAA-
GCTA and 5P-AGGAGGAAGCGGGAAGCTAT
(exon 9); 5P-CTGCACTCCAGCCTGGGCTA and
5P-CCCAGAAGGTTCACAGGAAT (exon 10); 5P-
TGGATAACATGGCATGGTTT and 5P-GCTTG-
AGGGGTAACACAGAT (exon 11); 5P-TACTCA-
TGTAGAGCTATTTA and 5P-GAATCCCTCCCA-
CAGAGAAT (exon 12); 5P-CTGTTTTGTGTGTT-
CAGCAT and 5P-ACAACTATTATGTACCCATA
(exon 13); 5P-TCTTTGCCCCCCCAACTTCT and
5P-TTCAGTAAAGTCTTGTTGTT (exon 14); 5P-
TTTCTAGTCCATCCTGCTTC and 5P-AGCAAA-
CTAATGGTTTTCTT (exon 15, proximal region);
and 5P-TCCTGTGGTGTTGAAGGGAA and 5P-
TTTACCTGATTGACACACTT (exon 15, distal re-
gion). Each exon was cloned with an original TA
cloning kit (Invitrogen) or a PCR-script Amp cloning
kit (Stratagene). The sequence of both strands of
each exon was determined with a DNA sequencer
(model 373A; Applied Biosystems).
For expression of human SGLT1 in Xenopus oo-
cytes, pBSXG (pBluescript KS(+) containing the
Xenopus L-globin gene promoter and terminator)
[10] was modi¢ed by deletion of the sequence be-
tween the HincII and ClaI sites in the multicloning
site region and insertion of an XbaI^NotI^ClaI linker
into the BglII site. The human SGLT1 cDNA was
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inserted into the modi¢ed plasmid with the use of
XbaI and ClaI. The Arg135CTrp mutation was in-
troduced into SGLT1 with the use of megaprimer
PCR mutagenesis [11,12]. For generation of the
exon 12-skipping form of SGLT1, the primer 5P-
GTGGTAACCAGATCATCGATTAGTCCCCAA-
AAGGCTCCCTTCCGGCAATCA was used, result-
ing in a ¢ve-amino acid extension before reaching a
stop codon. For generation of the intron 12-read-
through form of SGLT1, the primer 5P-GTGGTA-
ACCAGATCATCGATTATGCCAGAATGAC was
used, resulting in an 11-amino acid extension be-
fore reaching a stop codon. Plasmids were digested
with PstI, and mRNAs were prepared by in vitro
transcription (T7 mMESSAGE mMACHINE; Am-
bion).
2.3. Transport assay and immunoblot analysis
Oocytes at stage 5 or 6 were harvested from Xeno-
pus laevis females and injected with 50 nl (V50 ng)
of mRNA encoding wild-type or mutant human
SGLT1. They were then cultured for 3^5 days at
18‡C in a medium containing 88 mM NaCl, 1.1
mM KCl, 2.4 mM NaHCO3, 0.3 mM Ca(NO3)2,
0.41 mM CaCl2, 0.81 mM MgSO4, 15 mM
HEPES^NaOH (pH 7.6), penicillin (10 Wg/ml), and
streptomycin (10 Wg/ml) [13]. Glucose transport ac-
tivity in groups of three oocytes was assessed by
measurement of the uptake of 50 WM [14C]methyl-
D-glucose (CFB 76, Amersham Pharmacia Biotech)
in an uptake solution containing 100 mM NaCl,
2 mM KCl, 2 mM MgCl2, and 10 mM HEPES^
Tris (pH 7.5). After incubation at 20‡C for 1 h,
oocytes were immediately washed three times with
2 ml of ice-cold uptake solution. Individual oocytes
were lysed in 200 Wl of 10% SDS, and the amount of
released radioactivity was determined by a liquid
scintillation counter.
For immunoblot analysis, groups of ¢ve oocytes
were homogenized, and the homogenate was cen-
trifuged at 1000Ug for 30 s to eliminate yolk pro-
teins. The resulting supernatant was subjected to
SDS^PAGE, followed by immunoblot analysis with
rabbit polyclonal antibody to the peptide corre-
sponding to amino acids 564^575 of the deduced
SGLT1 sequence [14] and 125I-labeled protein A
[15].
2.4. Immunocytochemistry
Oocytes incubated for 3^5 days after mRNA in-
jection were ¢xed in 4% paraformaldehyde for 2 h at
room temperature, washed three times with phos-
phate-bu¡ered saline (PBS: 137 mM NaCl, 2.7 mM
KCl, 8 mM sodium phosphate^1.5 mM potassium
phosphate, pH 7.5), and incubated for 1 h at 20‡C
with antibody to SGLT1 in PBS containing bovine
serum albumin (1 mg/ml). After washing with PBS,
the oocytes were incubated for 1 h at 20‡C with
Alexa Fluor 546-conjugated goat antibody to rabbit
immunoglobulin G (A-11010, Molecular Probes) in
PBS containing bovine serum albumin (1 mg/ml) and
then washed an additional three times with PBS.
They were ¢nally mounted with FluoroGuard (Bio-
Rad) and observed with a confocal microscope (Mi-
cro Radiance 2000, Bio-Rad).
3. Results
3.1. Characterization of SGLT1 mutations
We sequenced the 15 exons of SGLT1 and their
£anking regions from the proband, her parents and
sister, and two control subjects. With the proband’s
DNA, ¢ve di¡erences were detected between the
sequences obtained and the original published
SGLT1 sequence (GenBank accession numbers
HUMSGLT01^12). The initial sequence analysis in-
dicated the presence of two heterozygous mutations.
To verify the presence of these mutations, we se-
quenced several clones of each exon. About half of
the patient’s exon 5 clones exhibited a CGGCTGG
transition at codon 135, which would result in an
Arg135CTrp mutation (Table 1); the remaining
exon 5 clones of the proband showed the normal
sequence. The patient’s father showed a similar pat-
tern at exon 5 in that 11 clones showed the same
CCT transition and the remaining seven clones ex-
hibited the normal sequence. The mother and sister
of the patient as well as the two normal control
subjects showed exclusively the wild-type sequence
for exon 5.
We detected another mutation, CAgtaggtatcat-
ctCCAgacct, in half of the clones derived from the
boundary of exon 12 and intron 12 of the patient
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Table 1
Number of cloned exons derived from SGLT1 of a GGM patient and her family
Exon Patient Mother Father Sister
Normal Mutant Normal Mutant Normal Mutant Normal Mutant
1 8 0 8 0
2 6 0 7 0
3 10 0 7 0
4 10 0 6 0
5 16 14 13 0 7 11 9 0
6 12 0 12 0
7 14 0 12 0
8 14 0 8 0
9 6 0 10 0
10 10 0 8 0
11 8 0 7 0
12 9 9 6 4 9 0 9 0
13 10 0 7 0
14 16 0 12 0
15p 16 0 7 0
15d 12 0 8 0
Genomic DNA derived from the patient, her parents, and a sister was subjected to PCR with primers that result in the ampli¢cation
of each of the 15 exons of SGLT1 (exon 15 was divided into proximal (p) and distal (d) regions). Individual clones corresponding to
each PCR product were sequenced, and the numbers of normal and mutant clones are shown.
Fig. 1. Mutation in intron 12 of SGLT1 in the patient and her mother. (A) Genomic DNA isolated from the patient, her parents,
and a control subject was subjected to PCR with a forward primer containing the normal (N) or mutant (M) intron 12 sequence and
the reverse primer, 5P-CCATACCAACTCCCGAGGAG. The PCR products were subjected to electrophoresis and stained with ethid-
ium bromide. (B) Genomic DNA was subjected to PCR with primers that amplify DNA fragments containing the splice donor site
for intron 12 of SGLT1 (forward, 5P-TACTCATGTAGAGCTATTTA; reverse, 5P-CCATACCAACTCCCGAGGAG). The PCR
products were treated with MvaI, which is predicted to generate 280-, 63-, 50-, and 26-bp fragments from the 419-bp normal sequence
and 136-, 136-, 63-, 50-, and 26-bp fragments from the 411-bp mutant sequence. The band above the expected 280-bp fragment for
the patient and her mother was shown by DNA sequencing to contain a mixture of the normal and mutant PCR products.
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(Table 1). Her mother showed the same change in
four of 10 clones, whereas all the corresponding
clones derived from her father and sister were nor-
mal. To con¢rm the mutation in intron 12, we ¢rst
performed PCR with a primer corresponding to the
normal sequence (5P-AATGAGCCAGTAGGTAT-
CAT) or a primer based on the mutant sequence
(5P-GAGAGTCAATGAGCCAGACC) (Fig. 1A).
With DNA derived from the patient or her mother
as template, PCR products were obtained with both
the normal primer and the mutant primer, whereas
DNA derived from the father or a control subject
yielded a PCR product only with the normal primer.
We also subjected PCR products spanning the intron
12 donor splice site to treatment with MvaI (Fig.
1B), given that the intron 12 mutation creates a
new site for this enzyme. A pattern of digestion
products consistent with the presence of the new
MvaI site was apparent only with DNA from the
patient and her mother (Fig. 1B).
The remaining three di¡erences between the
SGLT1 sequences found in all the sequences deter-
mined in the present study and the original published
sequence have also been detected by others (Gen-
Bank accession numbers HUMSGLT1, HSCB1E7,
HS65B7, and HS12724) and are as follows: exon 1,
5P-ATGGATAGTAGC (HUMSGLT01) versus 5P-
ATGGACAGTAGC (HUMSGLT1, HSCB1E7, and
four subjects in this study); intron 12, 5P-TT-
CCCCAGAGATCCACTAGTTTCTAGA (HUM-
SGLT09) versus 5P-T--CCCAGAGATCTTGAG-
CAGACACG (HS65B7 and six subjects in this
study); and intron 15, 5P-GCCGCAGAAGGGA-
GTC (HUMSGLT12) versus 5P-GCTGCAGAAGG-
GAAGTC (HS12724 and three subjects in this
study). These di¡erences may correspond to poly-
morphisms or to errors in the original sequence.
3.2. Glucose transport activity and immunoblot
analysis of SGLT1 mutants
To con¢rm that the SGLT1 mutations detected in
the proband are responsible for her disease, we in-
jected mRNA corresponding to the normal or mu-
tant SGLT1 alleles into Xenopus oocytes and mea-
sured glucose transport activity. Because the e¡ect of
the intron 12 mutation on splicing is not known, we
examined two possible forms of SGLT1 mRNA that
either contain the intron 12 sequence (intron 12-read-
through form) or lack the exon 12 sequence (exon
12-skipping form). The glucose transport activity of
oocytes expressing either of the three SGLT1 mu-
tants (Arg135CTrp, intron 12-read-through, or
exon 12-skipping) was 6 5% of that of those express-
ing the wild-type protein, and was therefore indistin-
guishable from that of water-injected oocytes (Fig.
2). Immunoblot analysis of injected oocytes revealed
that the wild-type transporter migrated as a di¡use
band with an apparent molecular size of 76 kDa
(Fig. 3). In contrast, the Arg135CTrp mutant mi-
grated as two high-molecular-weight aggregates and
a minor band corresponding to the position of the
core-glycosylated transporter [16]. Since the intron
12-read-through mutant and the exon 12-skipping
mutant are devoid of the antigenic site, no immuno-
logical analysis was performed on these mutants.
Fig. 2. Glucose transport activity of mutant SGLT1 proteins.
Xenopus oocytes were injected with mRNAs encoding the indi-
cated SGLT1 proteins (or with water) and the uptake of meth-
yl-D-glucose into the oocytes over a period of 1 h at 20‡C was
determined. Data are expressed as pmol of methyl-D-glucose
taken up per hour per oocyte and are means þ S.E.M. of values
obtained from 90 (wild-type), 39 (Arg135CTrp), 24 (intron 12-
read-through), and 24 (exon 12-skipping) oocytes.
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3.3. Immunocytochemical analysis of the
Arg135CTrp mutant
The tra⁄cking of SGLT1 in injected oocytes was
examined by immunocytochemical analysis with a
confocal microscope and antibody to the COOH-ter-
minal of SGLT1. The pattern of speci¢c staining in-
dicated that both the wild-type protein and the
Arg135CTrp mutant of SGLT1 were localized to
the cell surface (Fig. 4). The Arg135CTrp mutant
or wild-type SGLT1 that were fused with green £uo-
rescent protein at the COOH-terminal was also lo-
calized to the cell surface of oocytes, although nei-
ther of these fusion proteins exhibited signi¢cant
glucose transport activity (data not shown).
4. Discussion
More than 30 mutations of SGLT1 responsible for
GGM have been identi¢ed by Wright and coworkers
(http://archive.uwcm.ac.uk/uwcm/mg/search/120375.
html). The patient described in the present study ex-
hibited symptoms typical of GGM, and treatment
with fructose-substituted formula proved e¡ective.
The Arg135CTrp mutation detected in one of the
proband’s SGLT1 alleles was derived from her fa-
ther, and the mutation in intron 12 of her other
SGLT1 allele was inherited from her mother. Both
of these mutations abolish the glucose transport ac-
tivity of SGLT1, as shown by the expression of the
corresponding proteins in Xenopus oocytes. Our re-
sults thus indicate that the patient is a compound
heterozygote for mutations in SGLT1.
The mutation in intron 12 of SGLT1 identi¢ed in
the proband has not previously been detected in oth-
er GGM patients. Although the ¢nal processed form
of the transporter encoded by the mutant allele is not
Fig. 3. Immunoblot analysis of the Arg135CTrp SGLT1 mu-
tant. Xenopus oocytes were injected with mRNAs encoding ei-
ther wild-type SGLT1 or the Arg135CTrp mutant (or with
water). The cells were subsequently homogenized, the homoge-
nate was centrifuged to remove yolk, and the resulting superna-
tant (10 Wg of protein) was subjected to immunoblot analysis
with antibodies to SGLT1 and 125I-labeled protein A. Unla-
beled arrows indicate two high-molecular-weight aggregates of
the Arg135CTrp mutant.
Fig. 4. Localization of the Arg135CTrp mutant of SGLT1 at the cell surface. Xenopus oocytes were injected with mRNAs encoding
wild-type SGLT1 (A) or the Arg135CTrp mutant (B), or with water (C), and were subsequently subjected to immunocytochemical
analysis with antibodies to SGLT1 and Alexa Fluor 546-conjugated goat secondary antibodies. Bar in A indicates 0.2 mm.
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known, we examined the activity of two possible
such forms, an exon 12-skipping mutant and an in-
tron 12-read-through mutant, in the Xenopus oocyte
expression system. Our observation that neither of
these mutant proteins exhibited glucose transport ac-
tivity is consistent with previous data showing that
the COOH-terminal region of SGLT1 is important
for glucose recognition [17].
The primary defect of 21 missense mutants of
SGLT1 studied by Wright et al. [1] was mistra⁄ck-
ing, with preliminary results indicating that only one
missense mutant, Glu457CArg, retained the ability
to translocate to the plasma membrane of Xenopus
oocytes. Although the Arg135CTrp mutant has been
described previously [18], its properties were not
studied. We have now shown that this mutant is ex-
pressed in Xenopus oocytes at a level similar to that
of the wild-type protein, and that it undergoes ap-
parently normal tra⁄cking to the plasma membrane.
However, the mutant protein failed to exhibit glucose
transport activity and appeared to form aggregates.
These results indicate that the Arg135CTrp mutant
of SGLT1 is localized to the plasma membrane but is
non-functional, probably as a result of an abnormal
conformation. The roles of positively charged amino
acid in the vicinity of loops connecting transmem-
brane segments have been studied by von Heijne
and coworkers [19,20]. Thus, one possibility is that
the Arg135CTrp mutation a¡ects the translocation
of the following transmembrane segment [19]. An-
other possibility is that Arg135 exerts the ‘snorkel’
e¡ect and contributes to the ¢ne positioning of the
transmembrane segment [20]. In any event, this mu-
tant is a rare example of a non-functional SGLT1
protein and may be important for the molecular
studies on the topology of membrane proteins as
well as on the structural basis of sugar transport.
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